LEXICON PHARMACEUTICALS INC (LXRX)

Lexicon Pharmaceuticals to Host 2024 Investor Day

Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic...

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations...

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access ...

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a...

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with...

First Week of October 18th Options Trading For Lexicon Pharmaceuticals (LXRX)

Top Buys by Directors: Debbane's $1.1M Bet on LXRX

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year.

Notable Wednesday Option Activity: AI, LXRX, TMO

3 of the Fastest-Growing Stocks on the Planet in 2024

These hypergrowth stocks are expected to deliver sales growth of up to 1,106% in the new year.

7 Magnificent Stocks That Can Double Your Money in 2024

Triple-digit returns could be just a click of the buy button away.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual...

Commit To Buy Lexicon Pharmaceuticals At $1, Earn 30.4% Annualized Using Options

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid...

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following...

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant...

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies...

Lexicon Pharmaceuticals GAAP EPS of -$0.21 in-line, revenue of $0.16M misses by $1.9M (NASDAQ:LXRX)

Lexicon Pharmaceuticals reports Q3 GAAP EPS of -$0.21 in-line, but revenue of $0.16M misses by $1.9M.

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with...

Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023

THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial...

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data...

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting...

Lexicon Strengthens Management Team With Two New Executives

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS,...

New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA®...

Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027

EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END